Retinoblastoma is a cancer that develops in the retina, the light-sensitive layer at the back of the eye. It occurs mainly in infants and young children and may affect one or both eyes.
The cancer develops when changes involving the RB1 gene cause immature retinal cells to grow uncontrollably. Treatment aims first to protect the child's life, then preserve the eye and useful vision whenever this can be achieved safely.
At Apollo Cancer Centres, retinoblastoma care is planned by a multidisciplinary team that may include ocular oncologists, pediatric oncologists, ophthalmologists, interventional specialists, radiation oncologists, neuroradiologists, pathologists, genetic counsellors, anesthetists, and ocular rehabilitation professionals.
Risk Factors for Retinoblastoma
Retinoblastoma Signs and Symptoms
How Retinoblastoma Is Diagnosed
Diagnosis begins with a review of the child's symptoms, birth and developmental history, family history, and photographs showing an abnormal pupil reflection. Both eyes must be examined carefully because a small tumour may be present in the other eye even when only one eye appears abnormal.
Examination Under Anesthesia
Young children commonly require a detailed eye examination under anesthesia.
The ophthalmologist examines the entire retina and records:
Number and size of tumours
Location within the retina
Involvement of the optic disc or macula
Retinal detachment
Vitreous or subretinal tumour seeds
Involvement of the front of the eye
Potential for preserving useful vision
Retinal drawings, fundus photography, or digital imaging may be used to document the findings and monitor treatment response.
Indirect Ophthalmoscopy
Indirect ophthalmoscopy provides a wide view of the retina. It helps identify small or peripheral tumours that may not be visible during a routine eye examination.
Optical Coherence Tomography
Handheld optical coherence tomography may be used in selected children to assess the retina, macula, and small tumours in greater detail.
Ocular Ultrasound
Ultrasound can show:
A mass arising from the retina
Calcification within the tumour
Retinal detachment
Tumour size and location
Involvement of other structures within the eye
Calcification is common in retinoblastoma and can help distinguish it from some other childhood eye conditions.
MRI Of The Orbits And Brain
Contrast-enhanced MRI is the preferred cross-sectional imaging test.
It assesses:
Both eyes and optic nerves
Extension beyond the eyeball
Involvement of the tissues around the eye
Possible spread toward the brain
An associated pineal or other intracranial tumour
Treatment response in selected situations
MRI avoids ionising radiation, which is particularly important for children with heritable retinoblastoma.
CT Scan
CT can demonstrate calcification but is generally avoided when ultrasound and MRI can provide the required information. Limiting radiation exposure is especially important in children with a germline RB1 variant because they have an increased lifetime risk of additional cancers.
Direct Tumour Biopsy
Needle or incisional biopsy of a suspected retinoblastoma is generally avoided. Entering the eye can release tumour cells and increase the risk of cancer spreading outside the eye. Diagnosis is usually based on the characteristic eye-examination and imaging findings.
Bone Marrow And Cerebrospinal Fluid Assessment
Bone marrow examination or lumbar puncture is not routinely required for disease confined to the eye. These tests may be considered when there is evidence of optic-nerve extension, extraocular disease, neurological involvement, or metastatic spread.
Laboratory
Genetic and pathological assessment may include:
Histopathology: Confirms retinoblastoma after enucleation and distinguishes it from other retinal tumours.
Tumour differentiation: Identifies characteristic retinal structures and assesses how closely the tumour resembles developing retinal tissue.
Optic-nerve involvement: Determines whether tumour extends into the optic nerve and how close it comes to the surgical margin.
Choroidal invasion: Assesses whether cancer has entered the vascular layer beneath the retina.
Scleral involvement: Determines whether tumour has invaded the outer wall of the eye.
Anterior-segment involvement: Evaluates spread into structures at the front of the eye.
High-risk pathology: Deep optic-nerve, substantial choroidal, scleral, or extraocular invasion may indicate a need for additional treatment.
Tumour RB1 testing: May identify RB1 alterations within tumour tissue when an eye has been removed.
Germline RB1 testing: Determines whether the child carries an RB1 alteration in blood or another non-tumour sample.
Mosaicism assessment: More sensitive testing may be considered when clinical findings suggest heritable disease but routine blood testing is negative.
Family testing: Parents, siblings, or other relatives may be offered targeted testing when a disease-causing RB1 variant is identified.
There is no routine blood tumour marker for diagnosing or monitoring retinoblastoma. A negative blood RB1 result does not always completely exclude heritable risk, particularly when mosaicism is possible.
Treatment planning considers both the extent within each eye and whether the cancer has spread outside the eye.
Each affected eye may be classified from Group A to Group E:
Group A: Small tumours located away from critical structures, without tumour seeding.
Group B: Larger tumours or tumours closer to the optic disc or macula, without significant seeding.
Group C: Localised vitreous or subretinal tumour seeding.
Group D: Extensive or diffuse vitreous or subretinal seeding.
Group E: Extensive disease with little or no potential for useful vision or features suggesting a high risk of spread outside the eye.
The classification helps estimate the likelihood of preserving the eye. It does not replace assessment of vision or extraocular extension. Staging also considers whether one or both eyes are affected, pathological risk features, and whether useful vision can be preserved.
How Retinoblastoma Is Treated
Laser Therapy
Laser photocoagulation or transpupillary thermotherapy uses focused energy to destroy small retinal tumours or their blood supply. Several treatment sessions may be required, and the child remains under anesthesia during the procedure.
Cryotherapy
Cryotherapy applies extreme cold to destroy selected small tumours near the front of the retina. It may be repeated and can be combined with chemotherapy.
Plaque Brachytherapy
A small radioactive plaque may be temporarily attached to the outside of the eye to deliver radiation to a selected tumour. It may be used for a localised tumour that has not responded adequately to other eye-preserving treatments.
Enucleation
Enucleation removes the affected eyeball while preserving the eyelids and surrounding tissues. It may be recommended when:
The tumour fills most of the eye
Useful vision cannot be preserved
Painful glaucoma or other severe eye damage is present
There is a high risk of spread
Eye-preserving treatment is unlikely to be successful
Disease continues despite other treatment
For advanced disease in one eye, prompt enucleation may provide the safest and most effective treatment.
Removal Of Extraocular Disease
Surgery may occasionally be required for selected disease extending beyond the eye. It is combined with systemic treatment and, where appropriate, radiation therapy.
Intravenous Chemotherapy
Systemic chemotherapy can shrink intraocular tumours so they can be treated with laser or cryotherapy. This approach is often called chemoreduction. Medicines may include vincristine, etoposide, and carboplatin. Treatment selection depends on whether one or both eyes are affected, disease extent, age, and previous therapy.
Systemic chemotherapy may also be used for:
High-risk pathological features after enucleation
Extraocular disease
Metastatic disease
Trilateral retinoblastoma
Intra-Arterial Chemotherapy
Intra-arterial chemotherapy delivers medicine through a catheter placed into the artery supplying the eye. Medicines may include melphalan, topotecan, or carboplatin. The procedure requires a specialised interventional and pediatric anesthesia team.
Intravitreal Chemotherapy
Intravitreal chemotherapy delivers medicine directly into the vitreous cavity. It is used mainly for vitreous tumour seeds that are difficult to control with other treatments. Special injection techniques are required to minimise the risk of tumour spread outside the eye.
Treatment After Enucleation
Additional chemotherapy may be recommended if pathology identifies features associated with an increased risk of extraocular spread. Children without high-risk pathological features may not require further systemic treatment after complete enucleation.
High-Dose Chemotherapy
High-dose chemotherapy with autologous stem-cell rescue may be considered for selected metastatic or central nervous system disease. It is not required for typical intraocular retinoblastoma.
Targeted Therapy And Immunotherapy
Targeted therapies and immunotherapy do not currently have a routine established role in standard treatment for intraocular retinoblastoma. They may be studied in clinical trials or considered in exceptional advanced disease.
External Beam Radiation Therapy
External beam radiation can control retinoblastoma but is used less frequently because chemotherapy and focal treatments can often preserve the eye while limiting radiation exposure.
It may be considered for:
Extraocular disease
Central nervous system involvement
Selected tumours not controlled by other treatments
Palliative treatment of metastatic disease
Children with heritable retinoblastoma have an increased risk of additional cancers, and radiation may increase this risk further, particularly within the treated area.
Proton Therapy
Proton therapy may be considered when external radiation is necessary and reducing exposure to the brain, facial bones, opposite eye, or other developing tissues offers a meaningful advantage. It does not eliminate radiation-related risks and is not required for most children with intraocular disease.
Stereotactic Radiation Therapy
Highly focused radiation may be considered for selected intracranial or metastatic lesions. Suitability depends on the lesion's size, position, and relationship to critical structures.
The outlook is excellent when retinoblastoma is diagnosed while confined to the eye and appropriate treatment is available promptly. The likelihood of preserving the affected eye and useful vision depends on the tumour's size, location, seeding, and treatment response.
Children with heritable retinoblastoma require long-term follow-up because they have an increased risk of new retinal tumours in early childhood and other cancers later in life. Radiation exposure should be limited when an effective alternative is available.
Why Choose ACC for Retinoblastoma Treatment